A groundbreaking clinical trial evaluating the use of a monopolar Radiofrequency (RF) device coupled with continuous water cooling (CWC) for facial contouring and skin laxity has been completed, marking a significant advancement for skin aging treatments. Conducted by Yonsei University, the study holds implications for medical device professionals and dermatology experts.
Completed on January 11, 2026, the trial underscores the potential impact of RF-CWC technology in addressing skin aging, sagging, and laxity. The results offer opportunities for manufacturers, clinicians, and regulators to explore real-world applications.
In this article:
- How does the RF-CWC device work?
- What did the clinical trial evaluate?
- What is the market and clinical importance?
- Frequently Asked Questions
- Conclusion
- Disclaimer
How does the RF-CWC device work?
The RF-CWC device is designed to deliver monopolar RF energy to targeted areas of the skin while maintaining a controlled cooling system. The radiofrequency energy heats deeper layers of the dermis, stimulating collagen production and improving skin structure. The continuous water cooling ensures surface safety, minimizing the risk of burns or discomfort during application.
This combined approach of heating and cooling has made RF-CWC devices a compelling option for non-invasive facial contouring and skin rejuvenation. The device aligns with Medical Device Regulation (MDR) requirements for safety and performance.
What did the clinical trial evaluate?
Conducted under the sponsorship of Yonsei University, this clinical evaluation focused on several key parameters:
- Reduction of skin laxity
- Improvement in facial contouring
- Safety and patient tolerability of the RF-CWC device
The study population included individuals with visible signs of skin aging such as sagging and reduced elasticity. Preliminary findings indicate that the RF-CWC technology is both effective and well-tolerated, meeting key performance indicators for therapeutic devices.
Data from trials like this one are essential for regulatory documentation and external validation necessary for market authorization in various regions.
What is the market and clinical importance?
The completion of this trial supports two critical areas of interest:
- For manufacturers: The proven clinical efficacy strengthens the potential for commercial distribution, leading to possible regulatory approvals.
- For clinicians: Practitioners gain an innovative tool for addressing common patient concerns non-invasively.
- For regulators: Reliable data bolster the evidence base needed for device safety and performance evaluations under global market regulations.
Given ongoing consumer demand for non-invasive skin treatments, RF-CWC devices may occupy an expanding niche in dermatological and aesthetic applications.
Frequently Asked Questions
1. Who sponsored this clinical trial?
The sponsor of the trial was Yonsei University.
2. What conditions were addressed?
The trial targeted skin aging, sagging skin, and laxity among study participants.
3. Is the RF-CWC device already available on the market?
The regulatory status depends on performance validation and market authorization in specific regions. Further announcements may follow.
4. How does this study align with regulatory pathways?
This trial provides critical clinical evidence supporting the device’s efficacy and safety, key for meeting international regulatory requirements.
Conclusion
The successful completion of Yonsei University’s clinical trial highlights the transformative potential of RF-CWC technology in dermatological care. The device has been demonstrated to address skin aging and laxity with a focus on patient safety. This milestone may open pathways for future regulatory approvals and commercial opportunities. Affected stakeholders, such as clinical teams and manufacturers, should monitor ongoing developments closely.
Disclaimer
This article is for informational purposes only. It is not intended as legal or regulatory advice. Stakeholders should refer to official regulatory guidelines and professional consultation for compliance-related decisions.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07317089?term=medical+device